Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Drug Profile

Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Alternative Names: NCX 1021; NCX 1653; NCX 422; NCX 434

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Class Antiglaucomas; Eye disorder therapies; Nitroso compounds
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glaucoma; Ocular hypertension
  • Discontinued Diabetic macular oedema; Diabetic retinopathy

Most Recent Events

  • 20 Jul 2018 Discontinued - Preclinical for Diabetic macular oedema in France (Ophthalmic) (Nicox pipeline, July 2018)
  • 20 Jul 2018 Discontinued - Preclinical for Diabetic retinopathy in France (Ophthalmic) (Nicox pipeline, July 2018)
  • 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top